Recent Developments in the Treatment of Pancreatic Cancer
DOI:
https://doi.org/10.20344/amp.19957Keywords:
Carcinoma, Pancreatic Ductal/drug therapy, Carcinoma, Pancreatic Ductal/surgery, Carcinoma, Pancreatic Ductal/therapy, Pancreatic Neoplasms/drug therapy, Pancreatic Neoplasms/surgery, Pancreatic Neoplasms/therapyAbstract
Pancreatic duct adenocarcinoma is currently the sixth-leading cause of cancer death worldwide and the fourth in Europe, with a continuous increase in annual lethality in Portugal during the last two decades. Surgical en-bloc resection of the tumor with microscopic-negative margins and an adequate lymphadenectomy is the only possibility of long-term survival. As this type of cancer is a systemic disease, there is a high rate of recurrence even after curative resection, turning systemic therapy the core of its management, mostly based on chemotherapy. Neoadjuvant strategies for nonmetastatic disease showed significant improvement in overall survival compared with upfront surgery, namely in borderline resectable disease. Moreover, these strategies provided downstaging in several situations allowing R0 resections. Under these new oncologic strategies, several recent surgical issues were introduced, namely more aggressive vascular resections and even tumor resections in oligometastatic disease. This review revisits the state-of-the-art of surgical and oncological interventions in pancreatic duct adenocarcinoma and highlights recent advances in the field aiming to achieve higher survival rates.
Downloads
References
National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Pancreatic Cancer. 2022. [cited 2022 Mar 05]. Available from: https://seer.cancer.gov/statfacts/html/pancreas.html.
World Health Organization. Pancreas. Source: Globocan. 2020. [cited 2023 Jan 23] Available from: https://gco.iarc.fr/today/data/factsheets/cancers/13-Pancreas-fact-sheet.pdf.
da Costa PM, Marinho RT, Cortez-Pinto H, Costa L, Velosa J. Twentyfive years of increasing mortality from pancreatic cancer in Portugal. Pancreas. 2020;49:e2-3. DOI: https://doi.org/10.1097/MPA.0000000000001446
Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008-20. DOI: https://doi.org/10.1016/S0140-6736(20)30974-0
Iacobuzio-Donahue CA. Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut. 2012;61:1085-94. DOI: https://doi.org/10.1136/gut.2010.236026
Aune D, Greenwood DC, Chan DS, Vieira R, Vieira AR, Navarro Rosenblatt DA, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response metaanalysis of prospective studies. Ann Oncol. 2012;23:843-52. DOI: https://doi.org/10.1093/annonc/mdr398
Nothlings U, Wilkens LR, Murphy SP, Hankin JH, Henderson BE, Kolonel LN. Body mass index and physical activity as risk factors for pancreatic cancer: the multiethnic cohort study. Cancer Causes Control. 2007;18:165-75. DOI: https://doi.org/10.1007/s10552-006-0100-0
Pratapwar M, Stenzel AE, Joseph JM, Fountzilas C, Etter JL, Mongiovi JM, et al. Physical inactivity and pancreatic cancer mortality. J Gastrointest Cancer. 2020;51:1088-93. DOI: https://doi.org/10.1007/s12029-020-00441-9
Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. 2012;23:1880-8. DOI: https://doi.org/10.1093/annonc/mds491
Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008;393:535-45. DOI: https://doi.org/10.1007/s00423-007-0266-2
Duell EJ, Lucenteforte E, Olson SH, Bracci PM, Li D, Risch HA, et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012;23:2964-70. DOI: https://doi.org/10.1093/annonc/mds140
Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer. 2011;47:1928-37. DOI: https://doi.org/10.1016/j.ejca.2011.03.003
McWilliams RR, Maisonneuve P, Bamlet WR, Petersen GM, Li D, Risch HA, et al. Risk factors for early-onset and very-early-onset pancreatic adenocarcinoma: a Pancreatic Cancer Case-Control Consortium (PanC4) analysis. Pancreas. 2016;45:311-6. DOI: https://doi.org/10.1097/MPA.0000000000000392
Klein AP, Lindstrom S, Mendelsohn JB, Steplowski E, Arslan AA, Buenode-Mesquita HB, et al. An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS One. 2013;8:e72311. DOI: https://doi.org/10.1371/journal.pone.0072311
Singh RR, O’Reilly EM. New treatment strategies for metastatic pancreatic ductal adenocarcinoma. Drugs. 2020;80:647-69. DOI: https://doi.org/10.1007/s40265-020-01304-0
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317-27. DOI: https://doi.org/10.1056/NEJMoa1903387
White RR, Lowy AM. Clinical management: resectable disease. Cancer J. 2017;23:343-9. DOI: https://doi.org/10.1097/PPO.0000000000000291
Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22:9694-705. DOI: https://doi.org/10.3748/wjg.v22.i44.9694
Niesen W, Hank T, Buchler M, Strobel O. Local radicality and survival outcome of pancreatic cancer surgery. Ann Gastroenterol Surg. 2019;3:464-75. DOI: https://doi.org/10.1002/ags3.12273
Campbell F, Smith RA, Whelan P, Sutton R, Raraty M, Neoptolemos JP, et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009;55:277-83. DOI: https://doi.org/10.1111/j.1365-2559.2009.03376.x
Strobel O, Neoptolemos J, Jager D, Buchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16:11-26. DOI: https://doi.org/10.1038/s41571-018-0112-1
Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, Yu J, et al. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. Eur J Surg Oncol. 2019;45:1674-83. DOI: https://doi.org/10.1016/j.ejso.2019.04.007
Gilbert JW, Wolpin B, Clancy T, Wang J, Mamon H, Shinagare AB, et al. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Ann Oncol. 2017;28:2067-76. DOI: https://doi.org/10.1093/annonc/mdx180
Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833-46. DOI: https://doi.org/10.1016/j.jamcollsurg.2007.12.020
Oba A, Del Chiaro M, Satoi S, Kim SW, Takahashi H, Yu J, et al. New criteria of resectability for pancreatic cancer: a position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). J Hepatobiliary Pancreat Sci. 2022;29:725-31. DOI: https://doi.org/10.1002/jhbp.1049
Hartwig W, Gluth A, Hinz U, Koliogiannis D, Strobel O, Hackert T, et al. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer. Br J Surg. 2016;103:1683-94. DOI: https://doi.org/10.1002/bjs.10221
Fink DM, Steele MM, Hollingsworth MA. The lymphatic system and pancreatic cancer. Cancer Lett. 2016;381:217-36. DOI: https://doi.org/10.1016/j.canlet.2015.11.048
Shen CN, Goh KS, Huang CR, Chiang TC, Lee CY, Jeng YM, et al. Lymphatic vessel remodeling and invasion in pancreatic cancer progression. EBioMedicine. 2019;47:98-113. DOI: https://doi.org/10.1016/j.ebiom.2019.08.044
Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada Y, et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci. 2012;19:230-41. DOI: https://doi.org/10.1007/s00534-011-0466-6
Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014;156:591-600. DOI: https://doi.org/10.1016/j.surg.2014.06.016
Sabater L, Cugat E, Serrablo A, Suarez-Artacho G, Diez-Valladares L, Santoyo-Santoyo J, et al. Does the artery-first approach improve the rate of r0 resection in pancreatoduodenectomy?: A multicenter, randomized, controlled trial. Ann Surg. 2019;270:738-46. DOI: https://doi.org/10.1097/SLA.0000000000003535
Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268:215-22. DOI: https://doi.org/10.1097/SLA.0000000000002705
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378-82. DOI: https://doi.org/10.1038/nrclinonc.2011.44
Wei K, Hackert T. Surgical Treatment of Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2021;13:1971. DOI: https://doi.org/10.3390/cancers13081971
Maley WR, Yeo CJ. Vascular resections during the whipple procedure. Adv Surg. 2017;51:41-63. DOI: https://doi.org/10.1016/j.yasu.2017.03.004
Fancellu A, Petrucciani N, Porcu A, Deiana G, Sanna V, Ninniri C, et al. The impact on survival and morbidity of portal-mesenteric resection during pancreaticoduodenectomy for pancreatic head adenocarcinoma: a systematic review and meta-analysis of comparative studies. Cancers. 2020;12:1976. DOI: https://doi.org/10.3390/cancers12071976
Bacalbasa N, Balescu I, Barbu I, Stiru O, Savu C, Pop L, et al. Vascular resections in association with pancreatic resections for locally advanced pancreatic cancer. In Vivo. 2022;36:1001-6. DOI: https://doi.org/10.21873/invivo.12793
Murakami Y, Satoi S, Motoi F, Sho M, Kawai M, Matsumoto I, et al. Portal or superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head carcinoma. Br J Surg. 2015;102:837-46. DOI: https://doi.org/10.1002/bjs.9799
Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Buchler MW, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 2011;254:882-93. DOI: https://doi.org/10.1097/SLA.0b013e31823ac299
Boggi U, Del Chiaro M, Croce C, Vistoli F, Signori S, Moretto C, et al. Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer. Surgery. 2009;146:869-81. DOI: https://doi.org/10.1016/j.surg.2009.04.029
Bachellier P, Addeo P, Faitot F, Nappo G, Dufour P. Pancreatectomy with arterial resection for pancreatic adenocarcinoma: how can it be done safely and with which outcomes?: A single institution’s experience with 118 patients. Ann Surg. 2020;271:932-40. DOI: https://doi.org/10.1097/SLA.0000000000003010
Klompmaker S, Peters NA, van Hilst J, Bassi C, Boggi U, Busch OR, et al. Outcomes and risk score for distal pancreatectomy with celiac axis resection (DP-CAR): an international multicenter analysis. Ann Surg Oncol. 2019;26:772-81. DOI: https://doi.org/10.1245/s10434-018-07101-0
Oba A, Croce C, Hosokawa P, Meguid C, Torphy RJ, Al-Musawi MH, et al. Prognosis based definition of resectability in pancreatic cancer: a road map to new guidelines. Ann Surg. 2022;275:175-81. DOI: https://doi.org/10.1097/SLA.0000000000003859
van Hilst J, de Rooij T, Bosscha K, Brinkman DJ, van Dieren S, Dijkgraaf MG, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol Hepatol. 2019;4:199-207. DOI: https://doi.org/10.1016/j.pan.2018.05.021
Memeo R, Sangiuolo F, de Blasi V, Tzedakis S, Mutter D, Marescaux J, et al. Robotic pancreaticoduodenectomy and distal pancreatectomy: state of the art. J Visc Surg. 2016;153:353-9. DOI: https://doi.org/10.1016/j.jviscsurg.2016.04.001
Pedrazzoli S. Pancreatoduodenectomy (PD) and postoperative pancreatic fistula (POPF): a systematic review and analysis of the POPF-related mortality rate in 60,739 patients retrieved from the English literature published between 1990 and 2015. Medicine. 2017;96:e6858. DOI: https://doi.org/10.1097/MD.0000000000006858
Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584-91. DOI: https://doi.org/10.1016/j.surg.2016.11.014
Grutzmann R, Ruckert F, Hippe-Davies N, Distler M, Saeger HD. Evaluation of the International Study Group of Pancreatic Surgery definition of post-pancreatectomy hemorrhage in a high-volume center. Surgery. 2012;151:612-20. DOI: https://doi.org/10.1016/j.surg.2011.09.039
Duarte Garces AA, Andrianello S, Marchegiani G, Piccolo R, Secchettin E, Paiella S, et al. Reappraisal of post-pancreatectomy hemorrhage (PPH) classifications: do we need to redefine grades A and B? HPB. 2018;20:702-7. DOI: https://doi.org/10.1016/j.hpb.2018.01.013
Sohn TA, Yeo CJ, Cameron JL, Geschwind JF, Mitchell SE, Venbrux AC, et al. Pancreaticoduodenectomy: role of interventional radiologists in managing patients and complications. J Gastrointest Surg. 2003;7:209-19. DOI: https://doi.org/10.1016/S1091-255X(02)00193-2
Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142:761-8. DOI: https://doi.org/10.1016/j.surg.2007.05.005
Braga M, Pecorelli N, Ariotti R, Capretti G, Greco M, Balzano G, et al. Enhanced recovery after surgery pathway in patients undergoing pancreaticoduodenectomy. World J Surg. 2014;38:2960-6. DOI: https://doi.org/10.1007/s00268-014-2653-5
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30. DOI: https://doi.org/10.3322/caac.21442
Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349-61. DOI: https://doi.org/10.1016/j.cell.2011.11.025
Kulemann B, Pitman MB, Liss AS, Valsangkar N, Fernandez-Del Castillo C, Lillemoe KD, et al. Circulating tumor cells found in patients with localized and advanced pancreatic cancer. Pancreas. 2015;44:547-50. DOI: https://doi.org/10.1097/MPA.0000000000000324
Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15:333-48. DOI: https://doi.org/10.1038/s41575-018-0005-x
Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267:936-45. DOI: https://doi.org/10.1097/SLA.0000000000002234
Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576-85. DOI: https://doi.org/10.1016/S0140-6736(01)06651-X
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-77. DOI: https://doi.org/10.1001/jama.297.3.267
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D,Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073-81. DOI: https://doi.org/10.1001/jama.2010.1275
Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011-24. DOI: https://doi.org/10.1016/S0140-6736(16)32409-6
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395-406. DOI: https://doi.org/10.1056/NEJMoa1809775
Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, et al. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013;17:94-100. DOI: https://doi.org/10.1007/s11605-012-2064-6
Balachandran VP, Rojas LA, Sethna Z, Soares K, Derhovanessian E, Mueller F, et al. Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma. J Clin Oncol. 2022;40:s2516. DOI: https://doi.org/10.1200/JCO.2022.40.16_suppl.2516
Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-82. DOI: https://doi.org/10.1097/00000658-199912000-00006
Rutter CE, Park HS, Corso CD, Lester-Coll NH, Mancini BR, Yeboa DN, et al. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: an analysis of the National Cancer Data Base. Cancer. 2015;121:4141-9. DOI: https://doi.org/10.1002/cncr.29652
Hsieh MC, Chang WW, Yu HH, Lu CY, Chang CL, Chow JM, et al. Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy. Cancer Med. 2018;7:2328-38. DOI: https://doi.org/10.1002/cam4.1479
Cloyd JM, Heh V, Pawlik TM, Ejaz A, Dillhoff M, Tsung A, et al. Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med. 2020;9:1129. DOI: https://doi.org/10.3390/jcm9041129
Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111:782-94. DOI: https://doi.org/10.1093/jnci/djz073
Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801-10. DOI: https://doi.org/10.1016/S1470-2045(16)00172-8
Cascinu S, Berardi R, Bianco R, Bilancia D, Zaniboni A, Ferrari D, et al. Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a GISCAD phase II comparative randomized trial. Ann Oncol. 2019;30:v253-4. DOI: https://doi.org/10.1093/annonc/mdz247.001
Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020;5:285-94. DOI: https://doi.org/10.1016/S2468-1253(19)30327-9
Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315:1844-53. DOI: https://doi.org/10.1001/jama.2016.4324
Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14:317-26. DOI: https://doi.org/10.1016/S1470-2045(13)70021-4
Pietrasz D, Turrini O, Vendrely V, Simon JM, Hentic O, Coriat R, et al. How does chemoradiotherapy following induction FOLFIRINOX improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? An AGEO-FRENCH multicentric cohort. Ann Surg Oncol. 2019;26:109-17. DOI: https://doi.org/10.1245/s10434-018-6931-6
Katz MH, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, et al. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017;17:505. DOI: https://doi.org/10.1186/s12885-017-3441-z
Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC trial. J Clin Oncol. 2022;40:1220-30. DOI: https://doi.org/10.1200/JCO.21.02233
Ghaneh P, Palmer DH, Cicconi S, Halloran C, Psarelli EE, Rawcliffe CL, et al. ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J Clin Oncol. 2020;38:s4505. DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.4505
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
